Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis : A comparison with low molecular weight heparin
(1994) In Thrombosis and Haemostasis 71(2). p.214-219- Abstract
The aim was to investigate whether a truncated recombinant Tissue Factor Pathway Inhibitor (TFPI1-161) which lacked the third Kunitz-type domain and the basic c-terminal region, had an antithrombotic effect comparable to LMWH in a randomised double-dummy study. The experimental thrombosis was induced in jugular veins, in a total of 40 rabbits by a combination of destruction of the endothelium and restricted blood flow. Group 1: placebo, gr 2- LMWH 60 anti-FXa IU/kg, gr 3-5: 0.1, 1.0 and 10.0 mg/kg TFPI1-161. TFPI1-161 reduced the thrombus weights in all treated groups, significantly in doses of 1.0 and 10.0 mg/kg compared to placebo. The frequency of thrombosis and occlusive thrombosis were also... (More)
The aim was to investigate whether a truncated recombinant Tissue Factor Pathway Inhibitor (TFPI1-161) which lacked the third Kunitz-type domain and the basic c-terminal region, had an antithrombotic effect comparable to LMWH in a randomised double-dummy study. The experimental thrombosis was induced in jugular veins, in a total of 40 rabbits by a combination of destruction of the endothelium and restricted blood flow. Group 1: placebo, gr 2- LMWH 60 anti-FXa IU/kg, gr 3-5: 0.1, 1.0 and 10.0 mg/kg TFPI1-161. TFPI1-161 reduced the thrombus weights in all treated groups, significantly in doses of 1.0 and 10.0 mg/kg compared to placebo. The frequency of thrombosis and occlusive thrombosis were also significantly reduced in those doses. The antithrombotic properties of TFPI1-161 (1.0-10.0 mg/ kg) measured as thrombus weight, frequency of thrombosis and frequency of occlusive thrombosis was equivalent to the antithrombotic properties of LMWH. In the anti-FXa, APTT and PT-assays TFPI1-161 displayed a dose dependent increase of activity. Recombinant-TFPI1-161 did not influence the anti-FIIa-assay. No haemorrhagic side effects were noted.
(Less)
- author
- Holst, J. LU ; Lindblad, B. LU ; Bergqvist, D. ; Nordfang, O. ; Ostergaard, P. B. ; Petersen, J. G.L. ; Nielsen, G. and Hedner, U. LU
- organization
- publishing date
- 1994
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Thrombosis and Haemostasis
- volume
- 71
- issue
- 2
- pages
- 214 - 219
- publisher
- Schattauer GmbH
- external identifiers
-
- scopus:0028082448
- pmid:8191401
- ISSN
- 0340-6245
- language
- English
- LU publication?
- yes
- id
- 667c1511-2d85-42f0-aca8-976dab719f92
- date added to LUP
- 2018-04-06 13:48:43
- date last changed
- 2024-01-14 18:03:57
@article{667c1511-2d85-42f0-aca8-976dab719f92, abstract = {{<p>The aim was to investigate whether a truncated recombinant Tissue Factor Pathway Inhibitor (TFPI<sub>1-161</sub>) which lacked the third Kunitz-type domain and the basic c-terminal region, had an antithrombotic effect comparable to LMWH in a randomised double-dummy study. The experimental thrombosis was induced in jugular veins, in a total of 40 rabbits by a combination of destruction of the endothelium and restricted blood flow. Group 1: placebo, gr 2- LMWH 60 anti-FXa IU/kg, gr 3-5: 0.1, 1.0 and 10.0 mg/kg TFPI<sub>1-161</sub>. TFPI<sub>1-161</sub> reduced the thrombus weights in all treated groups, significantly in doses of 1.0 and 10.0 mg/kg compared to placebo. The frequency of thrombosis and occlusive thrombosis were also significantly reduced in those doses. The antithrombotic properties of TFPI<sub>1-161</sub> (1.0-10.0 mg/ kg) measured as thrombus weight, frequency of thrombosis and frequency of occlusive thrombosis was equivalent to the antithrombotic properties of LMWH. In the anti-FXa, APTT and PT-assays TFPI<sub>1-161</sub> displayed a dose dependent increase of activity. Recombinant-TFPI<sub>1-161</sub> did not influence the anti-FIIa-assay. No haemorrhagic side effects were noted.</p>}}, author = {{Holst, J. and Lindblad, B. and Bergqvist, D. and Nordfang, O. and Ostergaard, P. B. and Petersen, J. G.L. and Nielsen, G. and Hedner, U.}}, issn = {{0340-6245}}, language = {{eng}}, number = {{2}}, pages = {{214--219}}, publisher = {{Schattauer GmbH}}, series = {{Thrombosis and Haemostasis}}, title = {{Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI<sub>1-161</sub>) in experimental venous thrombosis : A comparison with low molecular weight heparin}}, volume = {{71}}, year = {{1994}}, }